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 Highlights 
 There is no single biomarker which can robustly identify senescent cells. 
 Widely used senescent cell biomarkers should be used in combination for accuracy.   
 Technologies like tangential flow filtration can be used to isolate senescent cells. 
 Other methods, like senolytic viruses, could be used to remove senescent cells. 
 
Abstract 
Aging is the main risk factor for many degenerative diseases and declining health. Senescent 
cells are part of the underlying mechanism for time-dependent tissue dysfunction. These cells 
can negatively affect neighbouring cells through an altered secretory phenotype: the 
senescence-associated secretory phenotype (SASP). The SASP induces senescence in healthy 
cells, promotes tumour formation and progression, and contributes to other age-related 
diseases such as atherosclerosis, immune-senescence and neurodegeneration. Removal of 
senescent cells was recently demonstrated to delay age-related degeneration and extend 
lifespan. 
To better understand cell aging and to reap the benefits of senescent cell removal, it is 
necessary to have a reliable biomarker to identify these cells. Following an introduction to 
cellular senescence, we discuss several classes of biomarkers in the context of their utility in 
identifying and/or removing senescent cells from tissues. Although senescence can be 
induced by a variety of stimuli, senescent cells share some characteristics that enable their 
identification both in vitro and in vivo. Nevertheless, it may prove difficult to identify a single 
biomarker capable of distinguishing senescence in all cell types. Therefore, this will not be a 
comprehensive review of all senescence biomarkers but rather an outlook on technologies 
and markers that are most suitable to identify and isolate senescent cells. 
 
Keywords: Aging, senescence, biomarkers, cell biology 
 
 1. Introduction 
1.1. Aging and cellular senescence  
Our society is rapidly aging and the incidence of age-related diseases, such as 
Alzheimer’s, diabetes and cancer is increasing (Christensen et al., 2009). If these trends 
continue, aging will become a major economic and social burden (Harper, 2014; Kankeu et 
al., 2013; Wimo et al., 2013). To avert this impending crisis, we must better understand why 
we age. Aging is a heterogenic process at both the organismal and cellular level. The number 
of contributing internal and external factors, such as epigenetic changes (Sinclair and 
Oberdoerffer, 2009) and the environment, make it difficult to categorize and prioritize the 
importance of each component. Such diversity has given rise to multiple theories regarding 
the root cause of aging (Harman, 1956; Park and Yeo, 2013; Wei et al., 2001), which 
sometimes contradict but more often complement one another. The variety of associated 
causes implies that aging is likely to be multifactorial in nature (Riess and Krüger, 1999; 
Sheikh et al., 2013). 
One known aging factor is cellular senescence. Senescent cells accumulate with age in 
organisms, albeit at different rates in the various organs (Erusalimsky and Kurz, 2005; Herbig 
et al., 2006; Jeyapalan et al., 2007; Paradis et al., 2001). Originally, cellular senescence was 
defined as a loss of replicative capacity (Hayflick, 1965) caused by a progressive shortening 
of the tandem repeats protecting chromosome ends (telomeres). This eventually leads to 
chromosomal damage and replicative arrest (Campisi, 1997). Interestingly, cellular 
senescence can also be induced by stress (Toussaint et al., 2000) and oncogenes (Bartkova et 
al., 2006), demonstrating that cellular senescence is not only caused by exhaustion of 
replicative capacity as first thought. Such heterogeneity of cellular senescence, which we will 
briefly discuss in the next paragraph, has led a field to sometimes unnecessary ambiguity, 
leaving researchers to disagree what cellular senescence entails (Burton and Faragher, 2015). 
For the purposes of this review, we define cellular senescence as a permanent (under 
physiological conditions) cell cycle arrest that is a result of cellular stress or damage, 
including but not limited to abnormal activation of oncogenes, telomere shortening and 
macromolecule accumulation (De Cecco et al., 2011). With this description we deliberately 
exclude developmental senescence, quiescent cells, and post-mitotic cells. 
[Table 1] 
 1.2. Senescent cells in health and disease 
Cellular senescence is thought to have developed as a safeguard to prevent damaged cells 
from accumulating and either becoming cancerous or causing cancer (Figure 1). However, 
accumulation of senescent cells in tissues is detrimental to the animal (Herbig et al., 2006; 
Jeyapalan et al., 2007) as these non-functional cells directly and indirectly damage 
surrounding cells (Salama et al., 2014). Examples of such damage include occupying niches 
required by competent cells to function (Lynch, 2004), secreting transforming, inflammatory 
and otherwise damaging components of the SASP (Campisi and d’Adda di Fagagna, 2007; 
Coppé et al., 2010, 2008), promoting tumour formation (Leikam et al., 2015; Zacarias-Fluck 
et al., 2015) and contributing to various age-related diseases such as atherosclerosis (Irvine et 
al., 2014; Wang and Bennett, 2012).  
While long-term accumulation of senescent cells is harmful to the organism, short-term 
senescence events prevent cancer (Kuilman et al., 2008), guide development (Muñoz-Espín et 
al., 2013) and improve tissue repair and wound healing (Demaria et al., 2014; Rodier and 
Campisi, 2011). One proposed mechanism to negate the long-term detrimental effects of 
senescent cells, while retaining their short-term beneficial functions, is to periodically purge 
them from the body. Regular elimination of p16-positive senescent cells from functionally 
wild-type mice slows time-dependent functional decline and extends median lifespan ~30% 
(Baker et al., 2016, 2011). Moreover, recent studies have demonstrated clearance of 
senescent cells from wild-type mice using small molecules which target the BCL-2 protein 
family (Chang et al., 2016; Zhu et al., 2015), lending credence to this approach as a 
therapeutic strategy. However, no method currently exists to accomplish this in humans, in 
large part because senescent cells cannot yet be reliably identified in living tissue. In the 
following sections, we will discuss biomarkers and their utility in identifying or eliminating 
senescent cells in a living organism. 
 
1.3. Characteristics of useful biomarkers 
A biomarker is a biological signature of a condition which enables one to evaluate if the 
biological system (organism, cell, etc.) possesses that condition or not. Many molecules, such 
as proteins, nucleic acids, and lipids, can be used as a biomarker. They can be found within 
the cell, in the adjacent extracellular area, or even systemically in the circulatory system. 
Importantly, no single marker currently provides an accurate representation of cellular 
 senescence. 
A useful biomarker must display several important features. First, it should be robustly 
associated with the condition. Although it is likely that (i) context, such as cell type, will be 
relevant and that (ii) it may not identify all cases of cellular senescence, it is crucial that the 
presence of the marker strongly correlates with a specific condition. Second, it is essential to 
know the threshold at which a marker becomes representative of the specific feature. Most 
proteins are expressed at basal levels in many cells, and simple evaluation of the presence or 
absence of the protein is not informative. For discrimination purposes, it is imperative to 
identify a clear threshold value which defines the cellular status. Finally, to be practical, a 
marker must be quantifiable using current technologies. Even a comprehensive understanding 
of a marker is not practically helpful unless we are able to monitor its levels or purify cells 
positive for it. 
In this review, we will emphasize markers of cellular senescence that would be practical 
to assay. Only single-cell markers of senescence will be discussed. Detailed reviews on 
systemic aging markers have been published previously (Falandry et al., 2013; Pallis et al., 
2014).  
 
1.4. The challenge and benefits of finding robust cellular senescence markers 
While cellular senescence has been linked to a number of predictable phenotypic traits 
and representative biomarkers (Table 1), senescent cells are still a heterogeneous population, 
and this fact significantly complicates a search for a robust senescence biomarker. Senescent 
cells arising from different stimuli exhibit measurably distinct proteomes (Aan et al., 2013; 
Dierick et al., 2002; G. J. Aan, 2011). Moreover, gene expression profiles of senescent cells 
are cell type-specific (Schnabl et al., 2003). Considering recent breakthroughs in our 
understanding of a need for personalized medicine, it is likely that variation will be seen not 
only between different senescent cell types but also between individuals. Importantly, 
potential reversibility of senescent cells has to be taken into account when evaluating what is 
and what is not cellular senescence. Although the main consensus in the field is to grant 
senescence a permanent and irreversible status, a number of studies have shown that cell 
cycle inhibition can be reversed in human senescent fibroblasts by inhibition of p53 and/or 
p16, two key pathways used to established cellular senescence (Beauséjour et al., 2003; Ide et 
al., 1983). More recently, it has been shown that inhibition of p38α/β MAPK lowers p16 
 levels and restores replicative capacity of aged mouse muscle stem cells (Cosgrove et al., 
2014). Unfortunately, these studies did not look into other senescence marker in their models. 
Therefore, it is still not clear if these aged cells are only forced into the cell cycle from p16-
dependant growth arrest or if is it is a complete or partial reversal of cellular senescence. 
Interestingly, cellular senescence can be prevented by activating autophagy, either with 
rapamycin treatment or Atg7 overexpression, in aged satellite mouse and human muscle cells. 
However, it is not clear from this data if cellular senescence can be reversed (García-Prat et 
al., 2016). Even if senescence could not be reversed, it is clear that a large senescence 
biomarkers can be affected by defined molecules and conditions, which is an important 
consideration when looking for and validating such markers. 
As cancer research has demonstrated, having robust, practical markers can enhance the 
research field in many ways (Henry and Hayes, 2012; Pallis et al., 2014). A reliable readout 
that identifies senescent cells would facilitate high-throughput screens as well as allow 
quantification of aging in various animal models. Most importantly, therapeutic techniques 
would benefit from robust markers to enable removal of senescent cells from tissues (such as 
blood filtering, Figure 3), stem cell preparations from aged autologous donors (Melk et al., 
2009) and identification of replicative exhaustion in stem cell expansions. One example of 
how such markers could be used is a strategy using selectively-lytic viruses, which are 
already used in oncology (Elsedawy and Russell, 2013). These are genetically modified 
viruses which replicate, lyse and kill cells in the presence (or absence) of specific gene 
products and, therefore, allow selective targeting. This strategy has successfully reached 
regulatory approvals in China and the USA for cancer treatment (Garber, 2006; Pol et al., 
2015). Theoretically, such a therapy could be applied to senescent cell removal as well.  
Currently, due to the heterogeneity of cellular senescence and ambiguity of the term 
(Table 1), there is no known universal biomarker which can selectively but broadly identify 
senescent cells in different tissues and extracellular environments. In this review, we will 
discuss a number of studies which have made significant strides towards the identification 
and validation of cellular senescence biomarkers.  
 
2. Surface markers & secretion profile 
Surface and external factors are ideal biomarkers, as they can be detected without 
intracellular delivery of a probe and without harming the cell. Multiple surface markers have 
 been associated with senescent cells, some more robust than others. Three major groups of 
such molecules will be covered: secreted factors, plasma membrane (PM)-associated proteins 
and PM lipid composition. 
 
2.1. Secreted biomarkers 
Secreted factors have excellent potential as biomarkers because detection methods can be 
contact-free, allowing measurement without disturbing the cells. However, secreted markers 
are intractable to cell isolation until technology is available which can detect the secretion of 
single-cells during the selection process.  
The senescence-associated secretory phenotype (SASP) has been observed in many 
different cell types (Acosta et al. 2008; Campisi et al. 2011). One study has defined many of 
the factors which are secreted by aged human fibroblasts and epithelial cells (Campisi et al., 
2008). This list of factors includes but is not limited to inflammatory mediators (such as IL-6 
and MIP-3a), growth factors (such as HGF, GRO, and IGF-binding proteins), detached cell 
surface molecules, and extracellular matrix components. Multiple studies have validated 
SASP and its related factors as robust markers of senescence, which makes them very 
promising candidates (Acosta et al., 2013; Sandeman et al., 2001).  
Interestingly, another secretory profile of senescent cells recently has been identified. The 
telomere-associated secretory phenotype (TASP) has been associated with replicative 
senescence (Braig et al., 2014; Jiang et al., 2008). It is not clear if this phenotype should be 
classified as separate from the SASP phenotype. However, it does provide some new and 
unique markers to consider. These include cathelin-related antimicrobial peptide (CRAMP), 
chitinase, stathmin, and EF-1α. Interestingly, one study has shown that CRAMP and chitinase 
levels highly correlate not only with replicative senescence but also with human aging in 
general (Lu et al., 2014). 
These secretory profiles are useful tools for evaluating general tissue or cell culture 
senescence. Some recent publications covered various ways of detecting such phenotypes. 
One such method is the SASP-responsive alkaline phosphatase (SASP-RAP) assay, where 
activity of secreted alkaline phosphatase is measured by a commercial chemiluminescence 
kit. SASP-RAP reliably detected senescence in rat renal tubular epithelial cells and mouse 
embryonic fibroblasts treated with etoposide, a DNA-damaging agent (Gu and Kitamura, 
2012). ELISA protocols have also been developed for an array of SASP components, 
 including IL-6 (Rodier, 2013). Moreover, it also may be possible to detect SASP by 
monitoring the known effects on surrounding cells. For example, senescent fibroblasts affect 
epithelial cell proliferation which can, in turn, be quantified as an indirect marker (Parrinello 
et al., 2005). 
Nevertheless, it is important to understand that there are some major limitations inherent 
to secretory markers. Firstly, the SASP may vary between cell types and between different 
stages of senescence (Coppé et al., 2010; Maciel-Barón et al., 2016; Rodier et al., 2009). 
Secondly, current technology does not permit the rapid, high-throughput analysis of single-
cell secretory phenotypes necessary to isolate a population on this basis. Although this 
technological gap currently prevents the use of a secreted marker for selective cell removal, 
secreted biomarkers are still applicable for general identification of senescent cells and 
potentially for diagnostic tests aiming to quantify the burden of cellular senescence in an 
individual. 
 
2.2. Plasma membrane-associated proteins 
Another set of surface structures which could be used for identifying and isolating 
senescent cells are plasma membrane-associated proteins, such as receptors and 
glycoproteins. As these structures are the main means of interaction between extracellular 
and intracellular compartments, their composition and functionality is essential for cell 
homeostasis.  
Several independent research groups have shown that plasma membrane (PM) 
glycoprotein composition is altered in aged cells (Poot et al., 1986; Wu et al., 2009). 
Glycoproteins are important components and play a role in many functions, including 
signalling in immune system and hormone responses (Ervasti, 2000; Li et al., 2010). There is 
a wide range of possible glycoprotein variants, and specific glycoprotein compositions have 
been linked to a senescence profile. For example, senescent human fibroblasts exhibit higher 
levels of concanavalin A, fucose, and glucosamine (Blondal et al., 1985).  
Expression changes in the concentration of PM-associated proteins could also be used 
as a senescence biomarker. Althubiti and colleagues have identified 107 PM-associated 
proteins upregulated in a human bladder cancer cell line induced to senesce by ectopic 
expression of p16 and p21. Ten of these upregulation events were validated by western blots 
and immunocytochemistry (Althubiti et al., 2014), while several additional candidates like 
 ICAM-1 had previously been reported to increase in senescent cells (Schnabl et al., 2003). 
Several standard methods exist to measure expression changes in PM proteins, including 
immunocytochemistry (Obradovic and Jurisic, 2012) and techniques utilizing other protein-
specific probes (Liu et al., 2005). Changes in the expression of PM proteins can also be 
detected with transductionally targeted recombinant viruses, which are able to enter only 
those cells with the appropriate ligand exposed on the PM. This has been accomplished in 
cancer cells already and readers are referred to an excellent review by Everts and Curiel for 
more information (Everts and Curiel, 2004). A similar strategy could be used to target 
senescent cells. The specific targeting of senescent cells holds promise both as a senescent 
assay and as a potential therapeutic. Transductionally targeted viruses could be engineered to 
selectively kill senescent cells or to carry a fluorescence reporter gene for identification 
(Perez et al., 2013) (Figure 4). 
 
2.3. Plasma membrane lipid composition 
The third type of marker which can be used to identify and isolate senescence cells is 
linked to PM lipid composition (Sud et al., 2007). Although PM lipid-based senescence 
biomarkers are less established and harder to detect compared to other surface signatures, 
some promising candidates and techniques have emerged which hold great potential for 
senescent cell identification and isolation.  
Membrane lipid composition and membrane biophysical properties change in senescent 
cells. Plasma membranes, due to altered lipid composition, become more rigid with age 
(Fulop et al., 2012a; Momchilova et al., 2014). Moreover, senescent cells increase in size 
compared to non-senescent analogues (Kim et al., 2015; Rodier and Campisi, 2011). This 
modifies many essential functions within the cell, such as diffusion, cell size, membrane 
fusion, chemical and electrical processes, cell elasticity and membrane stiffness (Pontes et al., 
2013). Such cellular mechanics have already been used as biomarkers to identify cancer cells, 
malaria-infected cells and primary cells (Darling et al., 2008; Suresh et al., 2005).  
A number of technologies have emerged to detect PM biomechanical and lipid 
composition differences between cells. For example, tangential flow filtration (Cai et al., 
2015) discriminates between cells based on membrane stiffness. Such a method has been 
successfully used to separate differentiated cells from pluripotent ones (Willoughby et al., 
2016). Moreover, a technology which selects cells based on cell mechanics has been used to 
sort red blood cells based on shape and deformation (Beech et al., 2012), which make this 
 sub-group of senescence markers even more viable.  
Another structure which could be used as a marker is a lipid raft (LR). LRs are small, 
dynamic structures in the plasma membrane that are high in cholesterol and low in 
unsaturated phospholipids (Brown, 2006). These structures recruit signalling components to 
the plasma membrane (Kabouridis, 2006). It has been shown that T cells from young subjects 
have a different LR distribution and functionality compared to T cells from older individuals, 
although it is still not clear if these changes are linked to senescent or aged cells in general 
(Fulop et al., 2012b; Larbi et al., 2006, 2004).  
LR dispersal can be measured using CTxB fluorescent molecules that bind to GM1 
gangliosides, which are LR markers (Holleran, 2003).  Moreover, it is possible to use specific 
fluorescent LR probes, such that quantifying the number of probes bound could be used as a 
means of identifying senescent cells (Mikhalyov and Samsonov, 2011). For a full analysis of 
the most current methods for studying membrane microdomains (including LRs and the 
signalosome) in intact cells, readers are advised to refer to Lagerholm’s review (Lagerholm et 
al., 2005).   
In summary, membrane lipid composition and its effects on cell biophysical properties 
represent a promising line of exploration for developing reliable, quantitative senescence 
markers.  
 
3. Intracellular senescence biomarkers 
Many intrinsic changes have been observed in senescent cells. While currently known 
intrinsic changes are more discrete and better defined compared to surface ones, they are 
harder to measure in live tissue. Three major groups of potential biomarkers will be covered: 
DNA-related markers, protective mechanism or damage signatures, and cell cycle genes. 
 
3.1. DNA-related senescence biomarkers  
It is still not clear if mutations significantly contribute to aging, but the cumulative 
number of mutations and the rate at which they accumulate increases with age in model 
organisms and senescent cells (Kennedy et al., 2012; Sedelnikova et al., 2004). Moreover, 
accelerated-aging diseases, such as Werner and Cockayne Syndromes, are linked to 
 malfunctioning DNA repair mechanisms (Rossi et al., 2010). Such findings make it tempting 
to speculate that DNA quality, metabolism, and maintenance are key mechanisms in the 
biology of aging. That being said, most of the changes which will be discussed are not 
exclusive to senescent cells and therefore use as a sole marker would yield a significant 
proportion of false positives. 
Various markers for DNA damage, such as γH2AX, 53BPI foci, Rad17, ATM and 
MDC1, are commonly used as conditional markers of cellular senescence (Lawless et al. 
2010; Wang et al. 2009; Sharma et al. 2012). γH2AX immunocytochemistry has been shown 
to effectively mark senescent fibroblasts (von Zglinicki et al., 2005). Although these markers 
are well established, they do not represent cellular senescence directly. γH2AX is a marker 
for DNA double-strand breaks (DSBs), which is neither necessary for nor exclusive to 
cellular senescence (Chapman et al., 2012). Similar limitations exist for other DNA damage 
related biomarkers (Awasthi et al., 2015). 
DNA synthesis markers can also serve as negative indicators for cellular senescence. 
DNA synthesis rate can be analyzed in 5-bromo-2’deoxyuridine (BrdU) or 5-ethynyl-2’-
dexyuridine (EdU) incorporation assays (Gratzner, 1982; Salic and Mitchison, 2008). Only 
cells that are undergoing DNA synthesis are able to incorporate transiently available BrdU or 
EdU nucleosides. The incorporation rate of such synthetic nucleosides is low in senescent 
cells, which suggests that DNA replication is near-absent (Voutetakis et al., 2015). Another 
assay for cell proliferation is based on immunostaining for marker Ki-67 (Urruticoechea et 
al., 2005). However, assays based on DNA synthesis would also identify other non-
replicative cells, such as quiescent cells and post-mitotic cells, which make such markers sub-
optimal if used alone.  
Telomere length can also be used as a biomarker for replicative senescence (Mather et 
al. 2011; Zietzer & Hillmeister 2014; Bekaert et al. 2005.). However, the shortening of 
telomeres associated with replicative senescence has yet to be translated into a common 
assay. There are several ways to measure telomere status in the cell. Measuring telomere 
length by quantitative PCR is one way (Cawthon 2002). Moreover, protocols have been 
designed which allow measurement of absolute telomere length (O’Callaghan and Fenech, 
2011) or telomere length of a single-cell (Wang et al., 2013). Unfortunately, these PCR-based 
approaches to telomere measurement require destruction of the cell. Fluorescence in situ 
hybridization (FISH) can be used to visualize the length of telomeres in fixed but intact cells 
(O’Sullivan et al., 2005; Ourliac-Garnier and Londoño-Vallejo, 2011), which retains 
 information such as subcellular localization. Moreover, FISH can be combined with flow 
cytometry to provide information on telomere length in thousands of cells (Baerlocher et al., 
2006; Hultdin et al., 1998). 
In addition to the direct measurement of telomere length, another potential aging 
marker is telomere dysfunction-induced foci (TIF) (Brugat et al., 2010; Sahin et al., 2011). 
TIF is a term used to describe telomeres which accumulated various DNA damage factors, 
such as γH2AX, ATM and Mre11 (Badie et al., 2010; Takai et al., 2003). TIF has been 
shown to increase in baboon fibroblasts that have undergone replicative senescence 
(Jeyapalan et al., 2007) and also has an effect on the metabolic status of the cell (Sahin et al., 
2011). Therefore, it may be possible to identify senescent cells by immunostaining for these 
factors at telomeres. 
Epigenetic changes, including senescence-associated heterochromatic foci (SAHF), 
can also be used as biomarkers for cellular senescence. Epigenetics largely determine cell-
state differences in a genetically identical population, such as within an organism (Sinclair 
and Oberdoerffer, 2009). Although epigenetic markers vary depending on the environmental 
context and type of cell (Kosar et al., 2011), epigenetic profiles have been defined for various 
conditions, including cancer (Dumitrescu, 2012; Mäbert et al., 2014) and aged human cells 
(Horvath, 2013). A specific heterochromatin profile has been linked to cellular senescence 
(Kosar et al., 2011; Narita et al., 2003). SAHFs, domains of heterochromatin that contribute 
to silencing of proliferative genes in senescent cells (Narita, 2007), can be detected by 
multiple methods, including DAPI staining and immunocytochemistry against SAHF 
components, such as HP1 (Aird and Zhang, 2013). Another novel assay, called chromatin in 
vivo assay (CiA), has the potential to be used in high-throughput screening for 
heterochromatin alterations (Jones, 2012). It may be possible to adapt it to report SAHFs.  
In summary, DNA-related signatures are some of the most prominent cellular senescence 
biomarkers. In addition to the fact that one or more of these markers can robustly be found in 
most senescent cells, the broad availability of methods for their detection makes this 
biomarker group extremely potent. Further discussion of how they can be used in 
combination with other markers to increase specificity will be discussed later in the review. 
 
3.2. Protective mechanism and damage markers 
Aging is closely linked to loss of damage repair and/or stress response capabilities, which 
results in the accumulation of various toxic by-products and other macromolecules (Chen et 
 al., 2007; Hipkiss, 2006). As a result, enzymatic by-products and activities of various 
lysosomal and proteosomal enzymes, which are responsible for aggregate clearance, are often 
altered in aged cells (García-Prat et al., 2016). The ability to detect such changes would help 
to identify and possibly isolate senescence cells.  
Perhaps the most frequently used biomarker for senescent cells is increased activity of β-
galactosidase (β-gal) (Bassaneze et al., 2008; Dimri et al., 1995), which reflects increased 
lysosomal mass (Kurz et al., 2000). Several techniques exist for β-gal detection, including 
fluorescence-based and cytochemical methods (Debacq-Chainiaux et al., 2009). However, β-
gal activity also increases in quiescence and in response to various forms of stress (Yang and 
Hu, 2005). Thus, β-gal as a sole marker may often yield false-positives and is best used in 
combination with other markers. A similar marker, α-fucosidase, has recently been reported 
(Hildebrand et al., 2013). While this marker boasts similar ease of detection, it remains 
uncertain if it is equally, more, or less specific for senescence than β-gal. 
Proteasomes, protein complexes responsible for degrading unneeded or damaged 
proteins, may also act as useful biomarkers for senescence. For example, 26 S proteasome 
activity is reduced in human primary senescent fibroblasts (Chondrogianni et al., 2003; 
Reinheckel et al., 1998; Torres and Perez, 2008), and 26 S proteasome activity has recently 
been measured using fluorogenic peptide substrates (Georgila et al., 2014). While this assay 
has not yet been applied to senescent cells, it may serve as a secondary marker in conjunction 
with other indicators of cellular senescence. 
Reactive oxygen species (ROS) can also be used for senescent cell detection. ROS are 
involved in oxidative stress, signalling and differentiation processes. ROS increase with age 
and correlate with many age-related cellular changes (Liochev, 2013). Furthermore, elements 
associated with protection against oxidative stress (Cox2, SOD, Mn and other antioxidants) 
often show reduced functionality in aged organisms (Espinoza et al., 2008; Paul et al., 2007).  
However, oxidative stress, like many other markers mentioned in this review, is only an 
indirect marker of senescence. It is not necessary for cells to have high ROS activity to 
become senescent. Furthermore, a low level of ROS, is not only useful but essential for 
normal cellular functions (Liochev, 2013). Conversely, high ROS levels are not always 
associated with senescence as they are sometimes linked to differentiation (Paul et al., 2014). 
This may make interpretation of results problematic if clear thresholds (and their deviation 
depending on environment) are not determined. Various assays, including commercially 
available kits, exist to measure oxidative stress markers and levels of intracellular ROS 
 (Starkov, 2010; Fan and Li, 2014). Most of these techniques rely on fluorescence detection 
with either flow cytometry/fluorescence microscopy or chemiluminescence. 
In summary, markers of cellular damage and protection mechanisms, such as ROS and β-
Gal, are well-known signatures of cellular senescence. While not exclusive to cellular 
senescence, these relatively easy-to-assay markers are frequently employed as companion 
diagnostics. 
 
3.3. Cell cycle genes  
Arrest of cell proliferation is a hallmark of a senescent cell, which means that genes 
responsible for such regulation can potentially be used as markers to identify which cells are 
senescent.  
During growth arrest, various cell cycle inhibitors such as p53 and p21 are activated 
(Campisi, 2005). p21waf is a cyclin-dependant kinase (CDK) inhibitor which acts by 
mediating pRB dephosphorylation. Its overexpression promotes cellular senescence as shown 
by β-gal activity, telomere length and DNA damage monitoring (Huang et al., 2004). 
Moreover, if p21waf is down-regulated in senescent cells, replicative capacity is restored 
(Schnabl et al., 2003). 
Another molecular alteration that is specific to senescent cells is the phosphorylation (and 
activation) of p53 at serine 15. This phosphorylation has been observed in normal human 
fibroblasts that have undergone replicative senescence (Webley et al., 2000), oncogene-
induced senescence (Ferbeyre et al., 2000), and other forms of senescence (Ghosh et al., 
2008). p53 and the related tumor suppressor p16INK4a are relatively robust markers of 
senescence as their expression is required to induce the characteristic permanent cell cycle 
arrest (Campisi and d’Adda di Fagagna, 2007; Krishnamurthy et al., 2004; Vandenberk et al., 
2011). However, these genes are not absolute markers of cellular senescence. For example, 
p53 is also responsible for apoptotic programmed cell death (Amaral et al., 2010). An assay 
relying solely on p53 levels, therefore, would not be able to discriminate senescent cells from 
those undergoing apoptosis. Furthermore, mutations may shift p53 activity patterns (Muller 
and Vousden, 2013). In such cases, p53 mutations, although tumorigenic, may not be linked 
to cellular senescence. Moreover, a reversible growth arrest state, known as quiescence, also 
depends on the aforementioned cell cycle inhibitors (Li and Bhatia, 2011). Although such 
context specificity would make these biomarkers unreliable if used alone, their use in a 
 combinatorial strategy could be very potent. 
 
4. Summary of most promising senescence biomarkers and combinatory approach 
4.1. Synopsis of the most practical markers for identification and isolation of 
senescent cells. 
    Some of the cellular senescence biomarkers are more practically viable either because of 
their relative robustness to accurately select senescent cells or existing technologies for their 
detection. In the following paragraph, we offer our opinion of the most promising senescence 
biomarkers. 
Firstly, markers for cell cycle genes (p16, p21, p53, Rb) and DNA synthesis (BrdU 
incorporation) provide a robust way to distinguish dividing cells from non-dividing cells. 
Considering that cell cycle arrest is a hallmark of cellular senescence, such markers carry 
great potential. That being said, if used alone, these assays would also identify non-senescent, 
non-proliferative cells, such as post-mitotic neurons or quiescent stem cells. Other senescence 
markers should be used in combination to alleviate such off-target effects.  
Secondly, due to the non-proliferative and dysfunctional nature of senescent cells, an 
accumulation of various intracellular junk and a stressed cellular repair mechanism are often 
observed. This makes a number of pathways a potential source for biomarkers, the most 
prominent example being β-gal activity in lysosomes. With a number of assays now available 
to detect such changes, this category of biomarkers may offer several strong candidates for 
diagnostic assays.  
Thirdly, considering recent developments in the ability to quantify cell biomechanical 
properties (Beech et al., 2012; Darling et al., 2008; Suresh, 2007) and plasma membrane 
elasticity alterations observed in senescent cells, new technologies could arise that would 
enable senescent cell identification and isolation. Similar approaches, based on tangential 
flow filtration, for example, have been used successfully to separate pluripotent cells from 
heterogeneous populations (Willoughby et al., 2016).    
Lastly, senescent cell surface components, such as ICAM-1 and NOTCH3, are very 
attractive biomarkers due to possibility of screening live cells without damaging them. 
Moreover, a number of techniques are available to achieve such aims, including 
immunocytochemistry, transductionally targeted viruses, FACS or magnetic cell sorting. 
Recent studies have also identified a large number of novel surface markers, which 
potentially may join the list of commonly used signatures for senescence (Althubiti et al., 
 2014).  
 
4.2. Using combinations of markers for a more robust and specific assay 
To achieve the highest possible specificity of an assay, a combination of the most 
prominent markers should be used. To date, it is common best practice in the cellular 
senescence research field to use a panel of markers to validate that cells are senescent (Acosta 
et al., 2013; Guo et al., 2009). p53, p16, β-gal and telomere length remain the most 
commonly used markers and their combination should accurately pinpoint senescent cells. 
Although essential, a four-piece requirement for identification and isolation is practically 
challenging and cost- and time-ineffective. We propose that a synthetic reporter (or lytic) 
virus could potentially be used as a single system with combinatorial potential. 
Similar strategies have been successfully used in the past for oncolytic viruses where 
input from multiple sources (genes, receptors etc.) was required for the function of the virus 
(Barker et al., 2003; Larson et al., 2015; Lee et al., 2010; Singh et al., 2012). For example, 
one study constructed an adenovirus in which gene E1a was under the control of the hTERT 
(human telomerase reverse transcriptase) promoter while the viral gene E1b was under the 
control of the HRE (hypoxia response element) promoter (Wang et al., 2008). Such a system 
allowed viral replication only in hypoxic cells with active telomerase, which are very 
common signatures for cancer cells. Although this particular example utilized two different 
promoters, much more elaborate bio-sensor circuits could be built to allow even greater 
specificity. Theoretically, most transcriptional signatures can be targeted with these viruses 
by genetically modifying viral promoters. Moreover, viral coat engineering allows specifying 
to which surface markers a viral particle can bind and consequently infect a target cell 
(Verheije and Rottier, 2012).  
 
5. Outlook 
In this review, we have covered a number of biological signatures, outlining their 
advantages and disadvantages as cellular senescence biomarkers. Some of them are widely 
accepted to mark an aspect of aging (telomeres, ROS etc.), while other molecules, such as 
lipid rafts, still require further validation as a practical marker. 
One of the major limitations of all these markers is the fact that the change is only 
 relative. For example, ROS is always present in the cells and small amounts are essential for 
intrinsic signalling. Although an increase in ROS levels is considered to be a marker of 
oxidative stress and possibly cellular senescence, at what point does the difference become a 
biomarker? Furthermore, can we robustly classify a measurement that can be considered a 
definitive indicator of senescence in all circumstances? These questions remain to be 
answered. Another important aspect is use of biomarker combinations. None of the markers 
can accurately and robustly detect senescent cells in all given instances. This is why it may be 
useful to use a combination of markers. Such combinations of complementing markers, such 
as the ones we have suggested, would offer a diagnostic with better accuracy and robustness. 
Although senescent cell markers are widely used in basic research, such signatures 
may also be useful in the clinic as well. Removal of senescent cells has been shown to have a 
positive effect on murine health. With increasing knowledge in immuno- and viro-therapies, 
new opportunities may arise to use senescence biomarkers in senescent cell removal 
procedures for therapeutic benefit.  
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Figure 1| Senescent cell role in health and disease. (i) Senescent cells accumulate in aged primates 
(Herbig et al., 2006; Oishi et al., 2014), and (ii) their removal might be impaired due to declining 
efficiency of the immune system. These accumulating senescent cells can (iii) damage surrounding 
cells (Biran and Krizhanovsky, 2015) and cause (iv) cancer (Leikam et al., 2015) and (v) other age-
related diseases, such as atherosclerosis (Erusalimsky and Kurz, 2005; Fischer et al., 2013; 
Nishimatsu et al., 2015). Although senescent cells play an important role in (vi) tumor suppression 
(Tominaga, 2015), (vii) wound healing (Demaria et al., 2014) and development, (viii) periodically 
removing them does not produce significant side-effects (Baker et al., 2016). Furthermore, (ix) 
removing senescent cells has been shown to increase health- and life-span in mouse models (Baker et 
al., 2016, 2011; Chang et al., 2016; Yi Zhu et al., 2015) 
  
  
Figure 2| Comparison of replicative senescence (RS) versus stress-induced premature 
senescence (SIPS). These two different types of senescence have measurably distinct proteomes (text 
in blue) but share many major senescence phenotypes (text in red). Moreover, it has been shown that 
different factors are responsible for induction of these phenotypes (Aan et al., 2013; Braig et al., 2014; 
Chondrogianni and Gonos, 2004; De Cecco et al., 2011; Golde and Miller, 2009). 
  
  
Figure 3| Schematic for the isolation of senescent cells from blood. This schematic demonstrates 
the principle of isolating senescent cells from the blood using a dialysis approach. This could be 
applied to humans to clear the blood of senescent cells, which are known to accelerate aging and 
cancer in neighbouring cells and to interfere with tissue homeostasis. 
 
 
 
Figure 4| Schematic representation of combinatorial senescent cell targeting with a synthetic 
reporter virus. This is an example of how a virus could be designed to select senescent cells based on 
a combination of markers. Viruses can be engineered to enter only cells which have a specific surface 
marker (transductional targeting). Moreover, simple (as demonstrated in the graph) or more elaborate 
synthetic genetic circuits could be used to allow reporter expression to occur only in cells possessing 
multiple markers for senescence, such as an active p16 promoter or an increased SA-β-galactosidase 
activity.  Replacing fluorescent proteins with suicide genes, which are functional only when expressed 
together, would allow generation of senescent-cell-specific lytic viruses. Such a senescent cell 
removal therapy could be used to remove senescent cells in an effort to increase health- and life-span 
of patients (Baker et al., 2016, 2011; Chang et al., 2016) 
 Table 1: Key cellular senescence phenotypic traits and related mechanisms 
Senescent cell phenotypic traits Reference 
Permanent cell cycle arrest Shay et al., 1991 
Persistent DNA damage response (DDR) Fumagalli et al., 2012 
Senescence-associated heterochromatic 
foci (SAHFs) and other epigenetic changes 
Narita et al., 2003 
Senescence associated secretory 
phenotype (SASP) 
Campisi, 2005 
Altered metabolism including increased 
lysosomal and proteosomal activity 
García-Prat et al., 2016 
 
  
 Table 2: A summary of the most practical cellular senescence markers 
Marker category Senescence marker Detection assays 
Secretion and 
surface  
SASP and TASP 
SASP-responsive alkaline phosphatase 
assay, ELISA, FACS, indirect assays based 
on secretions effect to surrounding cells 
Plasma membrane-associated 
proteins (concanavalin A, fucose, 
ICAM-1, DEP1, B2MG, NOTCH3, 
DCR2) 
Magnetic cell sorting (MACS), 
fluorescence-based cell sorting (FACS), 
immunocytochemistry 
Plasma membrane mechanics 
(solidity, cell size) 
Electrophysiology techniques, biophysical 
techniques (tangential flow filtration) 
Lipid rafts (LR) 
CTxB fluorescent molecules and other 
fluorescent probes 
DNA-associated  
DNA damage markers (γH2AX, 
53BPI, Rad17, ATR, ATM, MDC1, TIF) 
Immunocytochemistry 
DNA synthesis 
EdU or BrdU incorporation; Ki-67 
immunocytochemistry  
Telomere length Quantitative PCR, FISH 
SAHF CiA, DAPI staining, Immunocytochemistry 
Damage and 
repair 
mechanism  
Proteasome activity Fluorogenic peptide substrate assay 
Lysosomal activity (β-Galactosidase, 
α-Fucosidase) 
Fluorescence, chemiluminescent, 
cytochemical methods 
ROS 
DCFDH-DA 
fluorometry,  chemiluminescent oxygen 
detection reagents, FACS 
Cell-cycle 
related  
p16-pRB axis 
Immunocytochemistry, reporter assays 
p53-p21 axis 
DEC1 (BHLHB2) 
PPP1A 
 
  
 Table 3: A list of techniques which could be applied to remove senescent cells 
Technique Advantages Disadvantages 
Blood perfusion 
using surface 
markers or cell 
stiffness 
Variations of the technique already 
used in clinic 
Only able to remove senescent cells 
circulating in blood system  
Magnetic sorting 
using 
intracellular 
marker 
Established technology exists 
No clinical grade MAC sorter is currently 
available 
Lytic virus 
Variations of the technique already 
used in clinic 
Safety concerns of using virotherapy 
Stimulating the 
immune system 
Success and promise in oncotherapy 
Lack of robust and unique cell-surface 
marker for senescent cells 
Chemical 
compounds 
Applicable for therapeutic 
interventions 
Potentially high off-target effects 
 
